ATE258227T1 - Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv) - Google Patents

Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)

Info

Publication number
ATE258227T1
ATE258227T1 AT96916289T AT96916289T ATE258227T1 AT E258227 T1 ATE258227 T1 AT E258227T1 AT 96916289 T AT96916289 T AT 96916289T AT 96916289 T AT96916289 T AT 96916289T AT E258227 T1 ATE258227 T1 AT E258227T1
Authority
AT
Austria
Prior art keywords
hcv
hepatitis
virus
rna
transferase activity
Prior art date
Application number
AT96916289T
Other languages
English (en)
Inventor
Francesco Raffaele De
Licia Tomei
Sven-Erik Behrens
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11403393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE258227(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE258227T1 publication Critical patent/ATE258227T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96916289T 1995-05-25 1996-05-24 Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv) ATE258227T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95RM000343A IT1278077B1 (it) 1995-05-25 1995-05-25 Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
PCT/IT1996/000106 WO1996037619A1 (en) 1995-05-25 1996-05-24 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
ATE258227T1 true ATE258227T1 (de) 2004-02-15

Family

ID=11403393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916289T ATE258227T1 (de) 1995-05-25 1996-05-24 Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)

Country Status (13)

Country Link
US (2) US6383768B1 (de)
EP (1) EP0842276B1 (de)
JP (1) JP3187432B2 (de)
AT (1) ATE258227T1 (de)
AU (1) AU708431B2 (de)
BR (1) BR9609178A (de)
CA (1) CA2220873C (de)
DE (1) DE69631375T2 (de)
DK (1) DK0842276T3 (de)
ES (1) ES2211956T3 (de)
IT (1) IT1278077B1 (de)
PT (1) PT842276E (de)
WO (1) WO1996037619A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
WO1997012033A1 (en) * 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
JP2002510509A (ja) * 1998-04-02 2002-04-09 バイロファーマ・インコーポレイテッド Ｃ型肝炎ウイルスｎｓ５ｂ組成物およびその使用方法
US6639053B1 (en) * 1998-06-24 2003-10-28 Tetsuya Toyoda HCV-derived RNA polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
US6297005B1 (en) 1999-05-04 2001-10-02 Schering Corporation De novo priming activity of hepatitis C virus replicase
JP2003514562A (ja) * 1999-11-23 2003-04-22 バイロファーマ・インコーポレイテッド ポリメラーゼ組成物およびその使用方法
WO2001077371A1 (fr) 2000-04-07 2001-10-18 Shionogi & Co., Ltd. Procede de dosage de preincubation
KR20020010241A (ko) * 2000-07-28 2002-02-04 허영섭 Ｃ형 간염 바이러스 ｒｎａ-의존성 ｒｎａ 중합효소의대량 발현 기구 및 이로부터 발현된 융합단백질을 이용한효소활성 분석방법
EP1423522A2 (de) 2001-01-23 2004-06-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus-replikons und replikon- verbesserte zellen
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
WO2003089672A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
US20040142322A1 (en) * 2002-10-07 2004-07-22 Schering Corporation Continuous non-radioactive polymerase assay
WO2004091724A1 (en) * 2002-10-08 2004-10-28 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
US7807455B2 (en) 2003-02-13 2010-10-05 Merck Sharp & Dohme Corp. Method to confer cell culture replication activity to different Hepatitis C virus isolates
US8354518B2 (en) 2003-11-05 2013-01-15 Merck Sharp & Dohme Corp. HCV replicons containing NS5B from genotype 2B
EP1711516A4 (de) 2004-01-09 2009-12-30 Merck & Co Inc Hcv-rna-abhängige rna-polymerase
EP1735470B1 (de) * 2004-03-24 2010-04-21 Achillion Pharmaceuticals, Inc. Quantitativer test zum nachweis neu synthetisierter rna in einem zellfreien system sowie identifizierung von inhibitoren der rna-synthese
WO2006046039A2 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2006110762A2 (en) * 2005-04-11 2006-10-19 Achillion Pharmaceutical compositions for and methods of inhibiting hcv replication
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US20090203008A1 (en) 2006-06-08 2009-08-13 Ludmerer Steven W Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008082488A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
US8557848B2 (en) 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
WO2008112108A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. In vivo hcv resistance to anti-viral inhibitors
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
WO2009032116A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
ATE541845T1 (de) 2007-08-29 2012-02-15 Schering Corp 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
EP2408761B1 (de) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituierte indolderivate und verwendungsverfahren dafür
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
US8377928B2 (en) 2007-11-16 2013-02-19 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
MX2010013630A (es) 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0906026D0 (en) 2009-04-07 2009-05-20 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2614932T3 (es) 2009-09-29 2017-06-02 Janssen Products, L.P. Derivados de fosforoamidatos de nucleósidos
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0933426A1 (de) * 1990-06-25 1999-08-04 The Research Foundation for Microbial Diseases of Osaka University Non-A, Non-B Hepatitis Virus genomisches DNS und Antigenpolypeptide
AU652941B2 (en) * 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase

Also Published As

Publication number Publication date
IT1278077B1 (it) 1997-11-17
US6383768B1 (en) 2002-05-07
ES2211956T3 (es) 2004-07-16
JPH10507370A (ja) 1998-07-21
AU708431B2 (en) 1999-08-05
DE69631375T2 (de) 2004-11-04
CA2220873A1 (en) 1996-11-28
WO1996037619A1 (en) 1996-11-28
PT842276E (pt) 2004-05-31
US7399605B2 (en) 2008-07-15
AU5909896A (en) 1996-12-11
ITRM950343A0 (it) 1995-05-25
ITRM950343A1 (it) 1996-11-25
CA2220873C (en) 2000-10-24
JP3187432B2 (ja) 2001-07-11
EP0842276A1 (de) 1998-05-20
US20020164722A1 (en) 2002-11-07
BR9609178A (pt) 1999-05-04
EP0842276B1 (de) 2004-01-21
DK0842276T3 (da) 2004-05-03
DE69631375D1 (de) 2004-02-26

Similar Documents

Publication Publication Date Title
ATE258227T1 (de) Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)
Friebe et al. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication
NO934019L (no) Genomiske HCV sekvenser for diagnostiske og terapeutiske formaal
DE60142562D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
DK0484787T3 (da) HCV-specifikke peptider, fremgangsmåde til opnåelse deraf og anvendelse deraf
ATE281647T1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
TR199901602T2 (xx) Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
DE69333914D1 (de) Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
DE69334328D1 (de) Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
ATE337404T1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
DE69106141D1 (de) Non-a non-b sequenzen.
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
IL137458A0 (en) Genetic immunization with nonstructural proteins of hepatitis c virus
WO2002072776A3 (en) Cell culture system for synthesis of infectious hepatitis c virus
GB9912432D0 (en) Novel gbv sequence
AU783309C (en) Oligonucleotide primers for efficient reverse transcription of hepatitis C virus (HCV) RNA and methods of use thereof
AU2180997A (en) Isolation and/or amplification of hepatitis c virus (hcv) nucleic acids from samples suspected to contain hcv
Bridgen et al. Identification of coronaviral conserved sequences and application to viral genome amplification
AU2003250394A1 (en) Use of hepatitis c virus (hcv) p7 protein
AU2002337378A1 (en) Screening for antiviral affecting signal peptidase
Kumar Antisense regulation in polyoma virus
EP1424390A4 (de) Intakter hepatitis-c-virus und verfahren zu seiner kultivierung in einer in-vitro-zellkultur
KR970021307A (ko) HCV-신드비스(Sindbis) 재조합 바이러스 클론 및 그를 이용한 C형 간염 치료제의 탐색방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0842276

Country of ref document: EP